KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Invested Capital (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Return on Invested Capital for 9 consecutive years, with 4.02% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 537.0% year-over-year to 4.02%, compared with a TTM value of 4.02% through Dec 2025, up 537.0%, and an annual FY2024 reading of 4.36%, up 285.0% over the prior year.
  • Return on Invested Capital was 4.02% for Q4 2025 at Alnylam Pharmaceuticals, up from 2.96% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 6.98% in Q4 2022 and bottomed at 13.29% in Q3 2024.
  • Average Return on Invested Capital over 5 years is 0.07%, with a median of 0.53% recorded in 2025.
  • The sharpest move saw Return on Invested Capital plummeted -1455bps in 2024, then soared 1626bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.58% in 2021, then soared by 1307bps to 6.98% in 2022, then plummeted by -79bps to 1.48% in 2023, then crashed by -191bps to 1.35% in 2024, then surged by 398bps to 4.02% in 2025.
  • Business Quant data shows Return on Invested Capital for ALNY at 4.02% in Q4 2025, 2.96% in Q3 2025, and 0.49% in Q2 2025.